Literature DB >> 6814718

Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment.

S Adami, W B Frijlink, O L Bijvoet, J L O'Riordan, T L Clemens, S E Papapoulos.   

Abstract

In 10 patients with Paget's disease of bone and 2 patients with osteoporosis, we studied the effects of hypocalcemia and hypophosphatemia induced by disodium-(3-amino-1-hydroxypropylidene)-1,-bisphosphonate (APD) treatment on the serum concentration of PTH and 1,25-dihydroxy-vitamin D [1,25(OH)2D3] and on calcium absorption and balance. The fall in serum calcium and phosphate was associated with a rise in the serum concentration of PTH and 1,25(OH)2D3, coupled with increases in net calcium absorption and calcium balance. The concentration of 1,25(OH)2D3 was significantly related (P less than 0.001) to the serum calcium (r = 0.66), the serum phosphate (r = 0.78), and the serum PTH (r = 0.71), confirming the interrelated control of these parameters on 1,25(OH)2D3 production. Moreover the rise in 1,25(OH)2D3 caused an appropriate rise in calcium absorption (r = 0.74) and calcium balance (r = 0.86), showing that this vitamin D metabolite contributes as a hormone to calcium homeostasis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6814718     DOI: 10.1007/bf02411260

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  9 in total

1.  A specific method for the analysis of hydroxyproline in tissues and urine.

Authors:  D J PROCKOP; S UDENFRIEND
Journal:  Anal Biochem       Date:  1960-11       Impact factor: 3.365

2.  Response of 1alpha,25-dihydroxyvitamin D3 to hypocalcemia in human subjects.

Authors:  J P Bilezikian; R E Canfield; T P Jacobs; J S Polay; A P D'Adamo; J A Eisman; H F DeLuca
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

3.  A competitive protein-binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum.

Authors:  M A Preece; J L O'Riordan; D E Lawson; E Kodicek
Journal:  Clin Chim Acta       Date:  1974-07-31       Impact factor: 3.786

4.  Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  W B Frijlink; O L Bijvoet; J te Velde; G Heynen
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

5.  Measurement of 1,25-dihydroxycholecalciferol in man by radioimmunoassay.

Authors:  T L Clemens; G N Hendy; S E Papapoulos; L J Fraher; A D Care; J L O'Riordan
Journal:  Clin Endocrinol (Oxf)       Date:  1979       Impact factor: 3.478

6.  Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis.

Authors:  J C Gallagher; B L Riggs; H F DeLuca
Journal:  J Clin Endocrinol Metab       Date:  1980-12       Impact factor: 5.958

7.  Results of prolonged treatment of Paget's disease of bone with disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP).

Authors:  H R De Vries; O L Bijvoet
Journal:  Neth J Med       Date:  1974       Impact factor: 1.422

8.  Development of homologous immunological assays for human parathyroid hormone.

Authors:  R M Manning; G N Hendy; S E Papapoulos; J L O'Riordan
Journal:  J Endocrinol       Date:  1980-04       Impact factor: 4.286

9.  Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.

Authors:  D L Douglas; T Duckworth; R G Russell; J A Kanis; C J Preston; F E Preston; M A Prenton; J S Woodhead
Journal:  Lancet       Date:  1980-05-17       Impact factor: 79.321

  9 in total
  6 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

3.  Differentiation of Dihydroxylated Vitamin D3 Isomers Using Tandem Mass Spectrometry.

Authors:  Anisha Haris; Yuko P Y Lam; Christopher A Wootton; Alina Theisen; Bryan P Marzullo; Pascal Schorr; Dietrich A Volmer; Peter B O'Connor
Journal:  J Am Soc Mass Spectrom       Date:  2022-05-13       Impact factor: 3.262

4.  Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.

Authors:  F J van Breukelen; O L Bijvoet; W B Frijlink; H P Sleeboom; H Mulder; A T van Oosterom
Journal:  Calcif Tissue Int       Date:  1982-07       Impact factor: 4.333

5.  Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy.

Authors:  Hiroaki Ishida; Hirotaka Komaba; Naoto Hamano; Hideyuki Yamato; Kaichiro Sawada; Takehiko Wada; Michio Nakamura; Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2020-03-05       Impact factor: 2.626

6.  Prostaglandin-E2 Mediated Increase in Calcium and Phosphate Excretion in a Mouse Model of Distal Nephron Salt Wasting.

Authors:  Manoocher Soleimani; Sharon Barone; Jie Xu; Saeed Alshahrani; Marybeth Brooks; Francis X McCormack; Roger D Smith; Kamyar Zahedi
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.